HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey

This article was originally published in The Tan Sheet

Executive Summary

Switching oral contraceptives for women from Rx-to-OTC status was viewed as a "good idea" by a majority of respondents to a recent survey conducted by the Guideline Research Group (New York).

You may also be interested in...



Rx-To-OTC Switch Candidate Negative Lists "Stifle Innovation" - CHPA

FDA should consider all Rx-to-OTC switch candidates on a case-by-case basis and avoid creating "presumptive negative lists" of drug classes not suited to OTC use, the Consumer Healthcare Products Association stresses in Aug. 25 comments to the agency.

Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions

Merck should conduct a head-to-head comparison study of Mevacor use in prescription and over-the-counter settings, Endocrinologic & Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for lovastatin 10 mg.

OTC Emergency Contraceptive Restricted Access Supported By Gynetics Exec

Age requirements and other restrictions would allow emergency contraceptives (ECs) to be safely sold OTC, Gynetics Chief Financial and Operating Officer Jack Stover stated at an FDA public meeting June 29.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel